Holen Sie sich die Stockscreener-App
7.56
2.58%
0.19
Handel nachbörslich:
7.56
Aura Biosciences Inc Aktie (AURA) Neueste Nachrichten
Aura CEO to speak at Morgan Stanley healthcare event Sept. 16 - Stock Titan
Aura Biosciences (AURA) boosts finance chief with new stock grants - Stock Titan
COO at Aura Biosciences (AURA) lands new option and RSU package - Stock Titan
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aura Biosciences Grants Inducement Equity Awards to Newly Appointed Executives - Quiver Quantitative
Technical Reactions to AURA Trends in Macro Strategies - Stock Traders Daily
Aura Biosciences, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Long Focus Capital Management Expands Stake in Aura Biosciences Inc (AURA) With Strategic Add - GuruFocus
Aura (AURA) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison for the Current Session; Price Move - vinanet.vn
Aura Biosciences Extends Bel-sar Data With Long-Term Follow-Up Study - TipRanks
AURA Q1 2026 Earnings: Wider Net Loss of $0.50 Per Share Weighs on SharesEstimate Revision Count - vinanet.vn
AURA Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Commercial Pipeline CostsRevenue Warning Signal - vinanet.vn
Wall Street Zen Downgrades Aura Biosciences (NASDAQ:AURA) to Sell - MarketBeat
Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap - Stock Titan
Aura Biosciences (AURA): Long Focus Capital reports 4.9% ownership - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
HC Wainwright Raises Earnings Estimates for Aura Biosciences - MarketBeat
LifeSci Capital Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person - Stock Titan
Aura Biosciences (AURA) officer Erica Kratz files initial Form 3 insider report - Stock Titan
Aura Biosciences (AURA) COO Susan Abu-Absi files initial insider Form 3 - Stock Titan
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval - Seeking Alpha
AURA BIOSCIENCES, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $18 FROM $24 - webull.com
Aura refocuses clinical plans, reduces staff by 20% - The Business Journals
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adage Capital discloses 9.1M Aura Biosciences (AURA) shares under shared control - Stock Titan
Aura Biosciences (NASDAQ:AURA) Shares Gap Down on Disappointing Earnings - marketbeat.com
H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift - Investing.com Nigeria
Analysts Offer Predictions for AURA Q1 Earnings - marketbeat.com
Aura BiosciencesMay Offer Securities Up To $500 Million Aggregate - tradingview.com
Aura Biosciences (NASDAQ: AURA) sets $500M shelf and $200M ATM - stocktitan.net
Aura Biosciences Releases Q2 2026 Financial Results - AlphaStreet
HC Wainwright Lowers Aura Biosciences (NASDAQ:AURA) Price Target to $18.00 - MarketBeat
Aura Biosciences (NASDAQ:AURA) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS - marketbeat.com
Aura Biosciences Extends Cash Runway Into First Half 202 - Minichart
Form 8K Aura Biosciences Inc For: 11 August By Investing.com - Investing.com Nigeria
Aura Biosciences (AURA) doubles assets after $280.8M raise as losses mount - stocktitan.net
Aura Biosciences Q2 Loss Widens - marketscreener.com
Aura Biosciences Restructures, Refocuses on Ocular Oncology - TipRanks
Earnings Flash (AURA) Aura Biosciences Posts Q2 Net Loss $0.48 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Aura Biosciences, Inc. Q2 2026: Net loss $45.6M, EPS $(0.48) — 10-Q Summary - TradingView
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
AURA: Q2 net loss widened to $45.6M; $280.8M raised, restructuring shifts focus to ocular oncology - TradingView
Aura Biosciences Reports 45.6 Million Dollar Q2 Net Loss - Quiver Quantitative
AURA: Fully enrolled Phase 3 trial and strategic focus on ocular oncology extend cash runway to 1H 2029 - TradingView
Aura Biosciences, Inc. Announces Executive Changes - marketscreener.com
Aura Biosciences (AURA) Advances 4.42% to $8.04 as Oncology Pipeline Momentum BuildsProtective Put - dars.gov.et
Aura Biosciences (AURA) Drops 3.6% as Shares Test Critical $7.31 SupportTrend Continuation Trade - dars.gov.et
Responsive Playbooks and the AURA Inflection - Stock Traders Daily
Aura Biosciences (NASDAQ:AURA) Raised to Hold at Wall Street Zen - MarketBeat
Aura Biosciences Expands Authorized Shares and Incentive Plan - TipRanks
Aura Biosciences (AURA) Projected to Announce Quarterly Earnings on Wednesday - MarketBeat
AURA Q2'26 Earnings: EPS estimate is (0.38) USD - TradingView
InvestingPro Fair Value predicted Aura Biosciences’ 40% decline By Investing.com - Investing.com Nigeria
Aura Biosciences, Inc. Revenue Breakdown – NASDAQ:AURA - TradingView
AURA Q1 2026 Earnings: Wider-than-Expected Loss of -$0.50 per Share as Pipeline Investment ContinuesRevenue Breakdown Analysis - Vinanet
AURA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Understanding the Setup: (AURA) and Scalable Risk - Stock Traders Daily
Aura Biosciences Inc (AURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AURA|Aura Biosciences Inc|Price:7.155|Chg%:+0.105 - TradingKey
BlackRock (AURA holder) discloses 4.4% Aura Biosciences stake in amended filing - Stock Titan
Aura Biosciences Inc (AURA) Institutional Confidence - TradingKey
Aura Biosciences Inc (AURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):